Key Insights

Highlights

Success Rate

50% trial completion

Treatment Research

17 treatments under study, led by Rituximab

Related Conditions

Often studied with 5 related conditions

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 75/100

Termination Rate

50.0%

1 terminated out of 2 trials

Success Rate

50.0%

-36.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

200%

2 of 1 completed with results

Key Signals

2 with results50% success

Data Visualizations

Phase Distribution

2Total
Phase 2 (2)

Trial Status

Completed1
Terminated1

Trial Success Rate

50.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT03856216Phase 2Terminated

Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation

NCT00439556Phase 2Completed

Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant

Showing all 2 trials

Research Network

Common Treatments

  • Rituximab2
  • Tacrolimus2
  • Melphalan2
  • Peripheral Blood Stem Cell Transplantation1
  • Antithymocyte Globulin1

Active Sponsors

  • National Cancer Institute (NCI)2
  • M.D. Anderson Cancer Center2

Top Investigators

Related Conditions

  • Lymphoma2
  • Hematopoietic And Lymphoid Cell Neoplasm1
  • Acute Lymphoblastic Leukemia1
  • Cd20 Positive1
  • B Acute Lymphoblastic Leukemia1

Activity Timeline